Adaptin Bio (APTN) Short term Debt (2024 - 2026)
Adaptin Bio's (APTN) quarterly Short term Debt came in at $162208.0 in Q2 2026, down 32.61% quarter-over-quarter from $240698.0 in Q1 2026.
Analysis
Adaptin Bio (APTN) Short term Debt (2024 - 2026) Analysis & Trends
Adaptin Bio has disclosed Short term Debt across 2 years of filings, most recently posting $162208.0 for Q2 2026.
- In Q2 2026, Short term Debt changed N/A year-over-year to $162208.0; the TTM figure through Jun 2026 stood at $162208.0 (changed N/A YoY), while the FY2024 annual figure was $1.2 million, changed N/A from the prior year.
- Short term Debt came in at $162208.0 for Q2 2026 at Adaptin Bio, down from $240698.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $1.2 million in Q4 2024 to a low of $162208.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 162,208.00 |
| Mar 31, 2026 | 240,698.00 |
| Dec 31, 2024 | 1.25 Mn |